TIDMCRX

Cyprotex PLC

12 March 2015

Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex appoints Dr Rob Elsby as Leader of Drug Transporter Team.

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the appointment of Dr Rob Elsby as Leader of its Drug Transporter Team. Dr Elsby is a recognised expert in the drug transporter field, as exemplified by his numerous publications including co-authoring an International Transporter Consortium (ITC) whitepaper. These publications span such areas as the validation of in vitro transporter assays, predicting clinical DDI exposure changes for statins, and the role that transporter pharmacogenetics play in mediating ethnic differences in statin exposure. Dr Elsby's role at Cyprotex will involve leading the strategic direction of Cyprotex's transporter based assays both in terms of new research and its client-based services.

Prior to joining Cyprotex, Dr Elsby worked within a DMPK (Drug Metabolism and Pharmacokinetics) function at AstraZeneca where, over a period of 11 years, he helped develop the internal drug transporter scientific capability both practically and strategically. During this time his expert knowledge and technical interpretation of drug transporter science was routinely used towards the provision of drug disposition and clinical DDI (drug-drug interaction) risk understanding to global discovery and development project teams.

Dr Elsby will be presenting new research performed at Cyprotex in the field of transporters at the AAPS/ITC Joint Workshop on Drug Transporters in Baltimore, USA in April 2015. The research focuses on the impact of inhibitor pre-incubation time on uptake transporter interactions in vitro.

On joining Cyprotex, Dr Elsby said "I am very excited to be joining a leading scientific team that can utilise its specialist services/expertise to fully integrate in vitro ADME, transporter and toxicity data with PBPK (physiologically based pharmacokinetic) modelling approaches towards obtaining a more holistic prediction of a molecule's safety profile in humans."

Dr Anthony Baxter, Cyprotex's Chief Executive Officer said, "We are delighted to welcome Dr Elsby to our scientific team. Rob's experience in the extrapolation of in vitro drug transporter interactions to the clinical situation will be vital in assisting our customers in understanding the relevance of the data generated. Through expansion of its transporter capabilities, Cyprotex can now offer the full range of in vitro assays for regulatory DDI (drug-drug interaction) packages."

For further information:

 
 Cyprotex PLC                         Tel: +44 (0) 1625 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   ir@cyprotex.com 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad and broker to      Tel: +44 (0)20 7496 
  Cyprotex)                            3000 
 Shaun Dobson                         shaun.dobson@n1singer.com 
  Jen Boorer                           jennifer.boorer@n1singer.com 
                                       www.n1singer.com

Notes to Editors

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1000 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGUWWWUPAGQG

Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cyprotex Charts.
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cyprotex Charts.